<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lunde, Ketil</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Cell Therapy: Current State and Future Directions</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-33</style></pages><abstract><style  face="normal" font="default" size="100%">Bone marrow cells (BMCs) have the potential to differentiate into heart cells through a process called transdifferentiation. BMCs can be harvested either indirectly from the peripheral blood or directly through bone marrow aspiration and then administered in the heart via catheter-based intracoronary or intramyocardial injection during open heart surgery, or through retrograde coronary venous delivery.</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>